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Abstract
T-cell based IFN-c release assays do not permit distinction of active tuberculosis (TB) from successfully treated disease or
latent M. tuberculosis infection. We postulated that IFN-c and IL-2 cytokine profiles of antigen-specific T cells measured by
flow-cytometry ex vivo might correlate with TB disease activity in vivo. Tuberculin (PPD), ESAT-6 and CFP-10 were used as
stimuli to determine antigen-specific cytokine profiles in CD4 T cells from 24 patients with active TB and 28 patients with
successfully treated TB using flow-cytometry. Moreover, 25 individuals with immunity consistent with latent M. tuberculosis
infection and BCG-vaccination, respectively, were recruited. Although the frequency of cytokine secreting PPD reactive CD4
T cells was higher in patients with active TB compared to patients with treated TB (median 0.81% vs. 0.39% of CD4 T cells,
p=0.02), the overlap in frequencies precluded distinction between the groups on an individual basis. When assessing
cytokine profiles, PPD specific CD4 T cells secreting both IFN-c and IL-2 predominated in treated TB, latent infection and
BCG-vaccination, whilst in active TB the cytokine profile was shifted towards cells secreting IFN-c only (p,0.0001). Cytokine
profiles of ESAT-6 or CFP-10 reactive CD4 T cells did not differ between the groups. Receiver operator characteristics (ROC)
analysis revealed that frequencies of PPD specific IFN-c/IL-2 dual-positive T cells below 56% were an accurate marker for
active TB (specificity 100%, sensitivity 70%) enabling effective discrimination from non-active states. In conclusion, a
frequency lower than 56% IFN-c/IL-2 dual positive PPD-specific circulating CD4 T-cells is strongly indicative of active TB.
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Introduction
Interferon-c release assays (IGRA) are transforming diagnosis of
latent tuberculosis infection and improving diagnostic evaluation
of patients with active tuberculosis (TB) [1]. IGRA use IFN-c as
the sole read-out and provide only limited biological information
which is clinically interpreted in a binary fashion, whereby a result
indicates either presence or absence of infection. Moreover,
although IGRA responses are quantitatively higher in untreated
active TB than in treated TB [2,3], the considerable overlap in
responses between these patient groups precludes use of IGRA to
distinguish between these distinct states. According to a recent
meta-analysis, the sensitivity of IGRAs for diagnosis of active TB is
higher than tuberculin skin-testing, but the specificity of IGRAs to
distinguish between patients with active TB and non-active TB
suspects is still inadequately low [4].
The cellular immune response to intracellular pathogens
comprises a spectrum of T-cell subpopulations characterized by
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17813distinct cytokine secretion profiles and cell surface marker
phenotypes.Threemainsubsetsarerecognizedandcanbeidentified
on the basis of T-cell cytokine profiles: effector T cells that secrete
only IFN-c, effector-memory T cells that secrete both IFN-c and IL-
2 and central-memory T cells that secrete only IL-2. The relative
proportions of these three T cell subsets correlate with antigen load
in chronic viral infections [5,6]. Millington et al have previously
found that the relative proportions and frequencies of these three T-
cell subsets among M. tuberculosis antigen-specific T cells correlated
with pathogen burden and antigen load in TB patients. The
significant shift in cytokine profiles after anti-TB treatment led the
authors to propose this as a new approach for monitoring anti-
mycobacterial treatment but the technical approach was labour-
intensive and the number of patients was small [7].
We used a rapid 6 h-whole blood assay for intracellular cytokine
staining of IFN-c and IL-2 and flow-cytometry to measure and
compare antigen-stimulated T-cell cytokine profiles in 24 patients
with active untreated TB and 28 patients who had been
successfully treated. A threshold in IFN-c/IL-2 dual positive
CD4 T cells was established to distinguish active disease from
successfully treated disease. This threshold was further assessed in
50 healthy individuals without evidence for active tuberculosis.
Among those, 25 had a antigen-response profile compatible with
latent M. tuberculosis infection and 25 individuals had an immune
response consistent with BCG vaccination or infection with non-
tuberculous mycobacteria (NTM).
Materials and Methods
Subjects
Twenty-four patients with active tuberculosis and 28 patients with
successfully treated tuberculosis were prospectively recruited at the
university hospitals of the Saarland and of Freiburg, Germany
(table 1). All patients diagnosed with active tuberculosis had positive
cultures for M. tuberculosis or acid fast bacilli from one or more clinical
specimens, or clinical and radiologic features highly suggestive of
tuberculosis together with a good response to anti-tuberculosis
treatment (table 1). None had started treatment at the time of
enrolment. Patientswith successfully treated tuberculosis were studied
35.5620.4 years (interquartile range 20–50 years) after treatment.
Importantly, those patients had not suffered from relapse and did not
show any signs or symptoms compatible with active tuberculosis at
the time of analysis. Moreover, 25 healthy individuals (40.3611.6
years of age, 10 males, 15 females) with an immune status compatible
with latent infection with M. tuberculosis were recruited. This
classification was based immunologically on the presence of specific
immunity towards PPD and at least one of the M. tuberculosis specific
antigens ESAT-6 and CFP-10 [8]. In addition, 25 healthy individuals
with a positive immune response towards PPD in the absence of
specific immunity towards ESAT-6 and CFP-10 were analysed
(43.3612.7 years of age, 9 males, 16 females). Although the BCG-
vaccination status was not consistently known and this does not firmly
exclude latent infection, this very commonly observed response
pattern would be consistent with either BCG-vaccination or prior
NTM infection. These 50 individuals did not have any known
contact to a patient with active tuberculosis and did not show any
signs or symptoms of active disease. Medical history for HIV infection
was negative in all tested individuals; specific testing, however, was
only performed if clinically indicated.
Ethics statement
The study was approved by the local ethics committee
(A ¨rztekammer des Saarlandes), and written informed consent
was obtained from all participants.
Quantitation and characterization of antigen-specific
CD4 T cells within whole blood
Specific stimulation of CD4 T cells was performed directly from
heparinized whole blood for a total of 6 h. Titered amounts of
PPD (7.32 mg/ml, Tuberkulin for in vitro use (RT-50); Statens
Serum Institute, Copenhagen, Denmark), recombinant ESAT-6,
and recombinant CFP-10 (10 mg/ml each, Lionex, Braunschweig,
Germany) were used as stimuli as previously described [9–12].
Each antigen was stimulated separately and a total volume of
300 ml was used for each stimulus. As negative control, cells were
stimulated with diluent (phosphate buffered saline). Stimulation of
all samples including negative controls was done in the presence of
1 mg/ml anti-CD28 and anti-CD49d (clones L293 and 9F10; BD,
Heidelberg, Germany), respectively as described before [5,9–11].
In line with previous observations with other antigens [13], the
addition of these antibodies to stimulatory reactions with PPD led
to a 1.6160.40 fold increase in the percentage of IFN-c positive
CD4 T cells and a 1.5860.39 fold increase in IL-2 positive CD4 T
cells (n=7 individuals, data not shown). Multiparameter staining
was performed using anti-CD4 (clone SK3), anti-IFN-c (clone
4S.B3), anti-IL-2 (clone MQ1–17H12), and anti-CD69 (clone L78;
all antibodies from BD). At least 15.000 CD4 T cells were
analyzed on a FACS Calibur (BD) using Cellquest Pro 4.0.2
Table 1. Demographic and clinical characteristics of patients
with active and successfully treated tuberculosis.
Patients with
Active TB
Successfully
treated TB
n=24 n=28
Demographic characteristics
Mean age (years) 46.7618.7 58.7614.2
Sex (male/female) 9/15 21/7
Ethnicity
– white 19 28
– asian 4 -
– indian 1 -
Clinical characteristics of patients with disease
Location of disease
– Pulmonary 19*
– Extrapulmonary, among those 5
Lymphatic 1
Organ/bone 1
Skin 1
Disseminated 2
Basis of diagnosis
– Culture positive for MTB 12
– Acid fast bacilli on microscopy 9
– Response to treatment 3
Mean time after treatment (years) 0, treatment naı ¨ve 35.5620.4
Immune-based tests
PPD positive; number (percentage) 23 (95.8%) 23 (82.1%)
ESAT-6 and/or CFP-10 positive;
number (percentage)
16 (66.7%) 16 (57.1%)
*including one patient with pleural tuberculosis.
doi:10.1371/journal.pone.0017813.t001
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positive. Although CD8 T cells were not stained directly, there was
no detectable cytokine production among CD4 negative lympho-
cytes, indicating that CD8 T cells do not seem to contribute to
cytokine production in this experimental setting. Although
reactivity in the control stimulations was largely negligible, the
percentage of specific T cells was calculated by subtracting the
frequency obtained by the control stimulation. The lower limit of
detection was 0.05% as previously established [14].
Statistical analysis
Statistical analyses were performed using Prism V5.03 software
(Graphpad, San Diego, USA). Receiver operator characteristics
(ROC) analyses were performed to establish cutoffs of PPD
reactive CD4 T-cell frequencies and IFN-c/IL-2 dual cytokine
producing CD4 T cells. The cutoff with the highest diagnostic
sensitivity and specificity was determined using Youde index
statistics. The non-parametric Mann-Whitney test was used to
compare PPD reactive T-cell frequencies as well as the percentage
of dual cytokine secreting cells between patients with active disease
and individuals with successfully treated tuberculosis. If parame-
ters were compared between more than two groups, the non-
parametric Kruskall-Wallis test was used.
Results
To analyse immune response parameters that allow distinction
between patients with active tuberculosis and non-active states,
patients with active tuberculosis were first compared with a group
of individuals with a history of active tuberculosis where a prior
infection was definitely proven. Patients were included several
years after successful treatment. Together with the fact that none
of them had a tuberculosis relapse, this indicates that the likelihood
of overt remaining bacterial activity was rather low. Demographic
and clinical characteristics of the 24 patients with active
tuberculosis and 28 patients with successfully treated tuberculosis
are summarized in table 1. Whole blood from all individuals was
stimulated with PPD, ESAT-6 and CFP-10, and antigen-specific
CD4 T cells co-expressing CD69, IFN-c and/or IL-2 were
quantified using flow-cytometry. Among patients with active
disease, all except one (who had been on corticosteroids for 19
months) showed detectable T-cell reactivity towards PPD (95.8%),
whereas only 16 out of 24 individuals (66.7%) were reactive
towards the M. tuberculosis specific antigens ESAT-6 or CFP-10.
Among the 28 individuals with successfully treated tuberculosis, 23
(82.1%) reacted towards PPD, and only 16 (57.1%) were positive
towards ESAT-6 or CFP-10 (table 1 and figure 1). In general,
specific T-cell frequencies towards ESAT-6 and CFP-10 were
lower as compared to those towards PPD. Interestingly, patients
with active tuberculosis had higher frequencies of PPD reactive
cytokine-positive CD4 T cells (median 0.81%, interquartile range
(IQR) from 0.35–1.73%) than individuals with successfully treated
disease (median 0.39%, IQR 0.10–0.73%, p=0.02, Mann-
Whitney test, figure 1). However, as the overlap in T-cell
frequencies between the groups was substantial, it was impossible
to correctly assign the patients’ clinical status on an individual
basis (area under the curve AUC=0.63, 95% confidence interval
(CI) 0.46 to 0.79). At the optimum cutoff of .0.79% PPD reactive
CD4 T cells, the sensitivity and specificity for untreated active TB
were as low as 78% (95% CI: 56–93%) and 52% (95% CI: 31–
73%), respectively. Thus, neither the frequency of cytokine-
positive PPD reactive CD4 T cells nor reactivity towards ESAT-6
or CFP-10 allowed for a distinction between patients with active
tuberculosis from successfully treated patients.
In an attempt to improve diagnostic specificity for active TB,
PPD reactive CD4 T cells were stratified according to their
cytokine profile into populations secreting IFN-c only, IL-2 only
and dual-cytokine-secreting cells (figure 2). Stratification into these
subpopulations was only feasible in individuals who had PPD
reactive CD4 T-cell frequencies above the detection limit (23 of 24
patients with active tuberculosis and 23 of 28 patients with
successfully treated tuberculosis). Among successfully treated
patients, the cytokine profile was homogeneous and predominant-
ly consisted of IFN-c/IL-2 double-positive cells (figure 2A and B).
In contrast, the percentage of dual cytokine-secreting cells in
patients with active disease was significantly lower (p,0.0001,
Mann-Whitney test) and the profile showed a strong shift towards
cells expressing IFN-c only (figure 2C and D), whereas the
Figure 1. The frequency of antigen-reactive CD4 T cells does not allow distinction between patients with active tuberculosis (A-TB)
and successfully treated disease (T-TB). Whole blood from all individuals was stimulated with PPD, ESAT-6, or CFP-10 and antigen-specific CD4 T
cells co-expressing CD69, IFN-c and/or IL-2 were quantified using flow-cytometry. Although the difference in PPD reactive CD4 T-cell frequencies
between the two groups was significant (p=0.02, Mann-Whitney test), it was impossible to correctly assign the patients’ clinical status on an
individual basis. The median is depicted by the line.
doi:10.1371/journal.pone.0017813.g001
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(figure 2B and D). A receiver operator characteristics (ROC)
analysis revealed that a percentage of less than 56% of dual
cytokine-secreting cells identified patients with active tuberculosis
with a specificity of 100% (95% CI: 85–100%) and a sensitivity of
70% (95% CI: 47–87%; AUC 0.84, 95% CI: 0.72–0.96).
In a clinical setting, other individuals with non-active states such
as subjects with latent M. tuberculosis infection or individuals after
BCG vaccination or NTM infection may also typically present
with immunity towards PPD and/or the M. tuberculosis specific
antigens ESAT-6 and CFP-10. Based on the results shown in
figure 2, we hypothesized that these individuals would show a
similar cytokine profile as patients with successfully treated
tuberculosis. To assess this hypothesis, the cytokine profile of
PPD reactive CD4 T cells among 25 healthy individuals showing
concomitant reactivity towards ESAT-6 and/or CFP-10 (consis-
tent with latent M. tuberculosis infection) and 25 subjects without
ESAT-6/CFP-10 specific immunity (consistent with BCG vacci-
nation or NTM infection) was analysed. The median frequencies
of cytokine-positive PPD reactive CD4 T cells in latently infected
individuals was 0.48% (range from 0.14–2.57%) whereas it was
lower in ESAT-6/CFP-10 negative individuals (0.19%, range from
0.11–1.55%, p=0.002). When assessing the cytokine profile, the
percentage of dual-positive CD4 T cells was above the threshold of
56% in all cases with latent M. tuberculosis infection (figure 3A) and
with BCG vaccination response/NTM pattern (figure 3B). When
ROC analysis performed with patients with active disease as
compared to all individuals with non-active states (n=73), a
percentage of less than 56% dual cytokine-positive CD4 T cells
again was the optimum cut-off that revealed a sensitivity of 70%
Figure 2. Altered functional signature in patients with active tuberculosis. Typical examples of cytokine profiles of PPD reactive CD4 T cells
in patients with (A) successfully treated tuberculosis and (C) patients with active tuberculosis. Stimulated CD4 T cells were stratified into cells
expressing IFN-c only (upper left quadrant), IL-2 only (lower right quadrant), and dual-cytokine producing cells (upper right quadrant). The numbers
in the three quadrants refer to the relative percentage of each cell population. These percentages are displayed for all patients with successfully
treated tuberculosis (B) and active tuberculosis (D). The stippled line indicates the 56% threshold established by ROC analysis.
doi:10.1371/journal.pone.0017813.g002
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AUC 0.87, 95% CI: 0.77–0.97).
Of note, due to a generally lower frequency of ESAT-6 and
CFP-10 reactive T cells (see figure 1), robust cytokine profiles in
response to the M. tuberculosis specific antigens could only be
determined in 62.5% of patients with active tuberculosis, 35.7% of
individuals with successfully treated disease and 56.0% of latently
infected individuals. Interestingly, unlike PPD profiles, there was
no significant difference in the percentage of IFN-c/IL-2 dual
cytokine positive CD4 T cells in response to ESAT-6 or CFP-10
among the three groups of individuals and discrimination between
active and non-active disease states was poor (figure 4).
Taken together, detection of less than 56% PPD specific dual
cytokine-secreting T-cells is strongly indicative of active tubercu-
losis, whereas frequencies of PPD reactive dual cytokine-secreting
T-cells above 56% were observed in all non-active disease states as
well as active TB patients.
Discussion
We found that the cytokine profiles of PPD specific T cells
differed significantly between untreated patients with active TB
disease and non-active states. Non-active subjects had significantly
lower frequencies and a narrower range of PPD specific IFN-c
only-secreting T cells and significantly higher frequencies of dual
IFN-c and IL-2-secreting T cells. In contrast, the frequencies and
range of IL-2 only-secreting T cells were similar in the untreated
and non-active disease groups. The fact that all successfully treated
patients and all other individuals with non-active states had
frequencies of dual IFN-c and IL-2-secreting PPD specific T cells
above 56% means that frequencies of these T cells below 56%
were only seen in untreated patients, making this a 100% specific
marker for active disease. Frequencies of dual cytokine-secreting T
cells of less than 56% were only 70% sensitive for active
tuberculosis because 7 untreated patients had frequencies of these
T cells above 56%. There were no clinical, radiological or
microbiological features that clearly distinguished these 7 patients
from the remaining 16 who had frequencies of dual cytokine-
secreting T cells below 56%, although it is notable that 4 of the 7
had paucibacillary disease manifesting as cutaneous TB, bone TB,
pleural TB and lymph node TB. The remaining three had
bilateral sputum culture-positive pulmonary TB, consistent with
higher bacterial loads.
Relapse or re-infection in patients with previously treated TB is
not uncommon and is clinically very difficult to distinguish from
alternative pyrexial or respiratory illnesses when they present in
previously treated TB patients [15]. Our findings could potentially
help to determine whether or not previously treated patients have
active TB at the time of clinical presentation and diagnostic work-
up. However, before clinical application, our results including the
56% cutoff of dual-positive T cells need first to be confirmed in
Figure 3. Predominance of dual positive cytokine producing cells in non-active disease states. The percentages of cells expressing IFN-c
only, IL-2 only, and dual-cytokine producing CD4 T cells after PPD specific stimulation in individuals with immunity consistent with latent
M. tuberculosis infection (A) or BCG vaccination/NTM infection (B) were determined as described in figure 2.
doi:10.1371/journal.pone.0017813.g003
Figure 4. The percentage of ESAT-6 and CFP-10 specific IFN-c/
IL-2 dual positive CD4 T cells does not allow clear distinction
between active tuberculosis (A-TB) and non-active disease
states (T-TB or latent M. tuberculosis infection). This is evident
from the fact that 7 of 12 (58%) of latently infected subjects had ,56%
IFN-c/IL-2 dual positive ESAT-6-specific CD4 T cells The percentage of
dual positive CD4 T cells specific for ESAT-6 and CFP-10 was determined
as described in figure 2. As compared with PPD specific profiles with
higher overall frequencies, robust determination of profiles specific for
ESAT-6 and CFP-10 could only be determined if overall frequencies of
specific cells were above 0.1% (i.e. in 62.5% of patients with active
tuberculosis, 35.7% of individuals with successfully treated disease and
56.0% of latently infected individuals). The stippled line indicates the
56% threshold established for PPD specific T cells.
doi:10.1371/journal.pone.0017813.g004
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suspects with a lung disease different from tuberculosis or patients in
the setting of contact tracing. Moreover, the kinetics of the shifts in
cytokine profile under treatment need investigation as all our cured
patients had been treated many years or decades previously. We
therefore could not determine how soon after treatment the shifts in
cytokine profile take place although Millington et al noted
significant differences already in patients 3–6 months after
treatment initiation [7], suggesting the potential of this approach
fortreatmentmonitoring.However,theirstudyand ourswerecross-
sectional and determining the clinical utility of cytokine profiles for
treatment monitoring will require a larger, longitudinal study.
We have chosen individuals with a proven history of
tuberculosis several years after treatment to decrease the likelihood
of overt remaining bacterial activity. Given that successfully
treated and latent TB are characterized by a lower antigen load
than active disease, we postulated that the cytokine profile of latent
TB infection was similar to that of our treated TB group. Our
results confirmed this hypothesis and suggest that cytokine
profiling could make it possible immunologically to distinguish
not only between active and successfully treated TB, but also
between active disease and latent M. tuberculosis infection or
vaccination responses. In our analyses we have applied currently
used immune-based estimates to stratify potentially latently
infected subjects and potentially vaccinated subjects (see
figure 3A and B); however, this distinction is less important when
exploring an immune-based test to discriminate active disease
from any non-active state, as the cytokine profiles from all non-
active states were different from those observed in active
tuberculosis. In support of this, two recent studies indicate that a
preserved capacity to produce IL-2 after overnight or 72 h of
stimulation is a typical feature of latent M. tuberculosis infection
[16,17]. The non-active control subjects analysed in our study
were tested in the absence of any known recent tuberculosis
exposure. Based on our findings, it will be of considerable interest
to determine whether the cytokine profile can be altered in
suspects of active tuberculosis or in a setting of contact tracing; if
so, this could indicate a state of increasing bacterial burden and
consequently higher risk to develop active tuberculosis and could
represent a promising method that should be explored to target
tuberculosis preventive chemotherapy.
The whole blood approach has the potential to differentiate
active from treated or latent TB on an individual patient basis
within one working day. The assay simultaneously measures IFN-c
and IL-2 at the single cell level which is neither possible by IFN-c
ELISpot nor by ELISA, the two platforms used in the current
commercially available IGRAs. However, measurement of several
soluble cytokines by multiplex cytometric bead array in antigen-
stimulated supernatants or unstimulated plasma has identified
combinations of cytokines, and individual cytokines such as IP-10
and IL-6, that differ significantly between untreated and treated
patients but with considerable overlap in responses between the
groups [18]. Two recent studies have assessed IFN-c, IL-2 and
TNF-a induction after overnight stimulation of whole blood or
PBMC from patients with active tuberculosis and latently infected
individuals [19,20]. Although both studies focused on multi-
functionality of specific T cells to distinguish active disease from
latent infection, the sensitivity and specificity of this approach was
not explicitly assessed. Interestingly, however, in line with our data
and a recent study by Casey et al. [21], their results presented
indicate that the percentage of IFN-c/IL-2 double positive T cells
was higher in latently infected individuals; in that respect, it would
be interesting to comparatively assess sensitivities and specificities
for multifunctional and for IFN-c/IL-2 double positive T cells to
distinguish active from latent infection. Apart from cytokine
profiling, other immune-based approaches exist to distinguish
active disease from non-active states, such as the comparative
analyses of M. tuberculosis specific T-cell responses from blood and
specimens from the sites of disease. However, these approaches are
invasive and depend on the availability of specimens from the sites
of disease [22–26].
Changes in cytokine profiles could be a general feature of M.
tuberculosis specific T cells in active disease. In this study, however,
cytokine profiles of ESAT-6 and CFP-10 specific T-cells did not
significantly differ between untreated and treated patients, in
contrast to other recent studies. The reasons for this are unclear
but the frequencies of ESAT-6 specific and CFP-10 specific T cells
in the present study were determined ex vivo without enrichment
and were often near the threshold for detection. Other studies may
have detected lower frequencies of ESAT-6 and CFP-10 specific T
cells by use of immunomagnetic enrichment [7], the fluorescence-
immunospot platform [21] or longer antigen stimulation time [19–
21]. However, the frequencies of PPD reactive T cells we detected
were much higher than the frequencies of ESAT-6 and CFP-10
reactive T cells which may have made the distinction between the
cytokine profiles among the patient groups substantially more
discernible for the PPD specific T cells.
In conclusion, the PPD-based whole blood approach presented
here may be performed from less than 1 ml of whole blood and
produces results within one working day due to its short
stimulation time of only 6 hours. Thus, it holds promise for being
used in a routine clinical setting to rapidly allow distinction
between active and successfully treated disease or latent M.
tuberculosis infection.
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